Literature DB >> 27402890

Clinical manifestations of intermediate allele carriers in Huntington disease.

Esther Cubo1, María A Ramos-Arroyo2, Saul Martinez-Horta2, Asunción Martínez-Descalls2, Sara Calvo2, Cecilia Gil-Polo.   

Abstract

OBJECTIVE: There is controversy about the clinical consequences of intermediate alleles (IAs) in Huntington disease (HD). The main objective of this study was to establish the clinical manifestations of IA carriers for a prospective, international, European HD registry.
METHODS: We assessed a cohort of participants at risk with <36 CAG repeats of the huntingtin (HTT) gene. Outcome measures were the Unified Huntington's Disease Rating Scale (UHDRS) motor, cognitive, and behavior domains, Total Functional Capacity (TFC), and quality of life (Short Form-36 [SF-36]). This cohort was subdivided into IA carriers (27-35 CAG) and controls (<27 CAG) and younger vs older participants. IA carriers and controls were compared for sociodemographic, environmental, and outcome measures. We used regression analysis to estimate the association of age and CAG repeats on the UHDRS scores.
RESULTS: Of 12,190 participants, 657 (5.38%) with <36 CAG repeats were identified: 76 IA carriers (11.56%) and 581 controls (88.44%). After correcting for multiple comparisons, at baseline, we found no significant differences between IA carriers and controls for total UHDRS motor, SF-36, behavioral, cognitive, or TFC scores. However, older participants with IAs had higher chorea scores compared to controls (p = 0.001). Linear regression analysis showed that aging was the most contributing factor to increased UHDRS motor scores (p = 0.002). On the other hand, 1-year follow-up data analysis showed IA carriers had greater cognitive decline compared to controls (p = 0.002).
CONCLUSIONS: Although aging worsened the UHDRS scores independently of the genetic status, IAs might confer a late-onset abnormal motor and cognitive phenotype. These results might have important implications for genetic counseling. CLINICALTRIALSGOV IDENTIFIER: NCT01590589.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27402890     DOI: 10.1212/WNL.0000000000002944

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Comment on Clinical Profile of Genetically Proven Huntington's Disease Patients From Eastern India.

Authors:  Gustavo L Franklin; Carlos Henrique Camargo; Alex T Meira; Hélio A G Teive
Journal:  Ann Indian Acad Neurol       Date:  2020-06-24       Impact factor: 1.383

2.  Premanifest Huntington's disease: Examination of oculomotor abnormalities in clinical practice.

Authors:  Jessica Y Winder; Raymund A C Roos
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

3.  Incidence of Huntington disease in a northeastern Spanish region: a 13-year retrospective study at tertiary care centre.

Authors:  Paula Sienes Bailo; Raquel Lahoz; Juan Pelegrín Sánchez Marín; Silvia Izquierdo Álvarez
Journal:  BMC Med Genet       Date:  2020-11-23       Impact factor: 2.103

4.  Neurofilament Light Chain and Intermediate HTT Alleles as Combined Biomarkers in Italian ALS Patients.

Authors:  Assunta Ingannato; Silvia Bagnoli; Salvatore Mazzeo; Valentina Bessi; Sabrina Matà; Monica Del Mastio; Gemma Lombardi; Camilla Ferrari; Sandro Sorbi; Benedetta Nacmias
Journal:  Front Neurosci       Date:  2021-09-03       Impact factor: 4.677

Review 5.  What do we know about Late Onset Huntington's Disease?

Authors:  Sai S Chaganti; Elizabeth A McCusker; Clement T Loy
Journal:  J Huntingtons Dis       Date:  2017

6.  High frequency of intermediary alleles in the HTT gene in Northern Sweden - The Swedish Huntingtin Alleles and Phenotype (SHAPE) study.

Authors:  Jimmy Sundblom; Valter Niemelä; Maria Ghazarian; Ann-Sofi Strand; Ingvar A Bergdahl; Jan-Håkan Jansson; Stefan Söderberg; Eva-Lena Stattin
Journal:  Sci Rep       Date:  2020-06-17       Impact factor: 4.996

7.  Parkinsonism with a Hint of Huntington's from 29 CAG Repeats in HTT.

Authors:  Sipilä Jot
Journal:  Brain Sci       Date:  2019-09-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.